REPROCELL
banner
reprocell.bsky.social
REPROCELL
@reprocell.bsky.social
Better translating discoveries into therapies. Follow for updates about products, services, and industry news.
Building scalable allogeneic cell therapies? 𝗙𝗿𝗼𝗺 𝗯𝗹𝗼𝗼𝗱 𝘁𝘆𝗽𝗲 𝘁𝗼 𝗛𝗟𝗔 𝗜/𝗜𝗜 𝗞𝗢 – 𝗰𝗼𝗺𝗽𝗮𝘁𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗯𝘆 𝗱𝗲𝘀𝗶𝗴𝗻. REPROCELL's 𝗳𝗲𝗺𝗮𝗹𝗲 𝗛𝗟𝗔-𝗔 & 𝗛𝗟𝗔-𝗗𝗣𝗔𝟭, 𝗯𝗹𝗼𝗼𝗱 𝘁𝘆𝗽𝗲 𝟬+ 𝗵𝗼𝗺𝗼𝘇𝘆𝗴𝗼𝘂𝘀 𝗶𝗣𝗦𝗖 𝗹𝗶𝗻𝗲 (healthy 22-year-old donor) expands patient coverage and clinical flexibility.

Learn more: hubs.li/Q03_gq6Y0
January 19, 2026 at 1:46 PM
𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗮𝗻 𝗮𝗹𝗹𝗼𝗴𝗲𝗻𝗲𝗶𝗰 𝗶𝗣𝗦𝗖-𝗱𝗲𝗿𝗶𝘃𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗻𝗱 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝘀𝗰𝗮𝗹𝗲 𝗶𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗹𝘆? At REPROCELL, we offer 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆-𝗮𝗹𝗶𝗴𝗻𝗲𝗱, 𝗲𝗻𝗱-𝘁𝗼-𝗲𝗻𝗱 𝗚𝗠𝗣 𝗶𝗣𝗦𝗖 𝗠𝗖𝗕 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 with a unified workflow from donor to clinic, eliminating handoffs, delays, risk and complexity.

Explore our services: hubs.li/Q03ZNzSX0
January 7, 2026 at 10:24 AM
What if 𝗔𝗜 could design 𝗯𝗲𝘁𝘁𝗲𝗿 𝗴𝗲𝗻𝗲 𝗲𝗱𝗶𝘁𝗼𝗿𝘀 than what evolution gave us? 𝗢𝗽𝗲𝗻𝗖𝗥𝗜𝗦𝗣𝗥-𝟭 - the first AI-designed genome editing enzyme - might be exactly that.

In our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴, we explain:
✔What OpenCRISPR-1 is & how it was created
✔Why developers should care

👉Read the 𝗯𝗹𝗼𝗴: hubs.li/Q03YjfQp0
December 17, 2025 at 10:50 AM
🎉Congratulations to 𝗼𝘂𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗣𝗿𝗼𝗳𝗹𝘂𝗲𝗻𝘁 on their successful $𝟭𝟬𝟲𝗠 𝗿𝗮𝗶𝘀𝗲! Their latest funding round, led by Altimeter Capital and Bezos Expeditions - marks a major milestone in advancing 𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗲𝘀𝗶𝗴𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, agriculture, and beyond.

Find out more: hubs.li/Q03XR4ht0
Profluent bags $106m for AI-driven protein design tech
The Series B aims to fuel expansion into therapeutics, agriculture, and biomanufacturing applications.
hubs.li
December 12, 2025 at 10:16 AM
Check out our GMP iPSC MCB services:
- GMP iPSC MCB Services US: hubs.li/Q03X0fc-0
- GMP iPSC MCB Services Europe: hubs.li/Q03X0bv60
December 10, 2025 at 1:58 PM
If you’re exploring 𝐚𝐥𝐥𝐨𝐠𝐞𝐧𝐞𝐢𝐜 𝐢𝐏𝐒𝐂-𝐝𝐞𝐫𝐢𝐯𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 and planning 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲-𝐬𝐜𝐚𝐥𝐞 𝐜𝐞𝐥𝐥 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠, our latest article, featured in BioInformant, gives a clear look at how REPROCELL can support your program with a regulatory-ready GMP iPSC MCB.⁣

👉 Check out the article: hubs.li/Q03X0dK70
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach | BioInformant
Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing serv...
hubs.li
December 5, 2025 at 11:17 AM
REPROCELL isn’t just another iPSC vendor. We’re an 𝗲𝗻𝗱-𝘁𝗼-𝗲𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 covering the entire journey in-house: donor sourcing, reprogramming, GMP MCB and gene-editing support for clinical programs.

𝗢𝗻𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿, 𝗼𝗻𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻, 𝘇𝗲𝗿𝗼 𝗵𝗮𝗻𝗱𝗼𝗳𝗳𝘀.

Learn more: hubs.li/Q03WBDmb0
December 3, 2025 at 10:53 AM
Curious how to scale your iPSC-based therapy from bench to clinic? Check out the images 👇 to explore how REPROCELL delivers GMP-compliant iPSC MCB manufacturing - from donor sourcing and footprint-free reprogramming to full regulatory-ready cell banks under FDA/EMA/PMDA standards.
November 28, 2025 at 10:45 AM
The recording of our recent webinar - “Innovative Cell Technologies to Bioengineer Human Tissues In Vitro for Use in R&D and Modelling Human Disease” with Prof. Stefan Przyborski, is now live!

View the recording here 👉 hubs.li/Q03VW9Bz0
Explore our Alvetex® webpage: hubs.li/Q03VWjkS0
November 26, 2025 at 11:12 AM
Our custom research iPSC service supports research-grade stem cell projects, spanning the full workflow from human donor sourcing to differentiated derivatives.

Find out more: hubs.li/Q03Vm6GR0
November 21, 2025 at 11:45 AM
In our latest blog, REPROCELL dives into how 𝗲𝘅𝗼𝘀𝗼𝗺𝗲𝘀 are emerging as 𝗰𝗲𝗹𝗹-𝗳𝗿𝗲𝗲 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲𝘀 to conventional cell therapies.

Read more on our blog: hubs.li/Q03TXHKp0

Check out REPROCELL's iPSC-derived Exosomes: hubs.li/Q03TXJ8j0
November 19, 2025 at 11:24 AM
We’re excited to launch highly purified iPSC-derived exosomes for pre-clinical & advanced research, made at our Japan GMP facility. Derived from StemRNA™ clinical-grade iPSCs, available in liquid & lyophilized forms, ideal for anti-aging & collagen production studies.

Learn more: hubs.li/Q03TbmM50
November 14, 2025 at 10:15 AM
Advancing an iPSC therapy program? We offer GMP iPSC MCB manufacturing in the EU (via Histocell) and the US (REPROCELL USA).
• EU (Histocell): hubs.li/Q03SMwJz0
• US (REPROCELL USA): hubs.li/Q03SMtVL0
Ready to discuss your project requirements? Submit an inquiry or email us: 𝗶𝗻𝗳𝗼-𝗲𝗺𝗲𝗮@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹.𝗰𝗼𝗺
November 12, 2025 at 11:43 AM
Join our webinar on 🗓️6 Nov 2025 with Prof. Stefan Przyborski: learn how Alvetex® scaffolds can help you build layered, human-relevant tissue models.

🕛 EMEA 12:00 UK / 13:00 CET
🕛 US 12:00 EST / 09:00 PST

👉Seats are filling fast, you can save your spot here: hubs.li/Q03P57jb0
November 3, 2025 at 10:06 AM
REPROCELL is thrilled to have attended the 2025 Cell & Gene Therapy Symposium – Mid-Atlantic in Washington D.C., where researchers, clinicians and industry united to advance cell & gene therapies from discovery to patient care.
October 31, 2025 at 10:35 AM
Join us on 𝟲 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 2025 for a webinar on 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗖𝗲𝗹𝗹 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝘁𝗼 𝗕𝗶𝗼𝗲𝗻𝗴𝗶𝗻𝗲𝗲𝗿 𝗛𝘂𝗺𝗮𝗻 𝗧𝗶𝘀𝘀𝘂𝗲𝘀 𝙄𝙣 𝙑𝙞𝙩𝙧𝙤 𝗳𝗼𝗿 𝗨𝘀𝗲 𝗶𝗻 𝗥&𝗗 𝗮𝗻𝗱 𝗠𝗼𝗱𝗲𝗹𝗹𝗶𝗻𝗴 𝗛𝘂𝗺𝗮𝗻 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 with 𝗣𝗿𝗼𝗳. 𝗦𝘁𝗲𝗳𝗮𝗻 𝗣𝗿𝘇𝘆𝗯𝗼𝗿𝘀𝗸𝗶.

🕛 EMEA Session: 12:00 UK / 13:00 CET
🕛 US Session: 12:00 EST / 9:00 PST

🔗𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 here: hubs.li/Q03Q0-hk0
October 30, 2025 at 10:18 AM
We're excited to add a 23-year-old, Caucasian male (A⁺ blood type) donor line to our StemRNA™ clinical iPSC portfolio. Multiple iPSC clones from this donor are now ready for testing, the perfect foundation for advancing your cell therapy development.

Explore more: hubs.li/Q03PSDPF0
October 24, 2025 at 9:28 AM
Excited to share that thanks to the MSCRF Manufacturing Assistance grant, we’re building a full-scale GMP/CDMO facility (Maryland) for large-batch hiPSC-derived & MSC therapy manufacturing, turnkey services from banking and gene-editing to differentiation & production.

Read more: hubs.li/Q03PGxWh0
October 22, 2025 at 1:49 PM
We're excited to announce that REPROCELL & Histocell have jointly achieved AEMPS GMP certification for the manufacturing of 𝗶𝗣𝗦𝗖 𝗠𝗮𝘀𝘁𝗲𝗿 & 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗖𝗲𝗹𝗹 𝗕𝗮𝗻𝗸𝘀 using REPROCELL’s 𝗦𝘁𝗲𝗺𝗥𝗡𝗔™ 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖𝘀, produced at Histocell’s newly certified GMP facility in Spain.

Learn more: hubs.li/Q03PgkGb0
October 20, 2025 at 9:35 AM
In our recent webinar Dr Luana Ferrara showed how Qkine’s high-purity, animal-free growth factors & cytokines address reproducibility challenges in stem cell, organoid & disease models.

Couldn’t join us live? The 𝗳𝘂𝗹𝗹 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴 is now online, on our 𝗬𝗼𝘂𝗧𝘂𝗯𝗲 channel → hubs.ly/Q03MVw-D0
October 17, 2025 at 10:39 AM
𝗥𝗲𝗽𝗿𝗼 𝗠𝗦𝗖𝟭𝟬 now include 𝗢𝗻𝗰𝗼𝗣𝗮𝗻𝗲𝗹 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 at every stage — from donor fibroblasts → iPSCs → iMSCs. Get assurance of chromosomal integrity via G-band karyotyping + NGS-based variant screening across 400+ cancer-related genes.

Check out Repro MSC10 here: www.reprocell.com/product-cata...
October 15, 2025 at 7:07 AM
Thrilled to see REPROCELL featured by @bioinformant.bsky.social.
From iPSCs, MSCs, and iMSCs, to MCB generation, clinical or research gene editing, we support your stem cell projects end-to-end.
Clinical #StemCell Services: REPROCELL's experts in cell therapy manufacturing will take you through all the stages of your regenerative medicine project

www.reprocell.com/clinical-ste...
October 10, 2025 at 9:07 AM
𝗥𝗘𝗣𝗥𝗢𝗖𝗘𝗟𝗟 𝗨.𝗦.𝗔., 𝗜𝗻𝗰., has been awarded a 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗔𝘀𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗴𝗿𝗮𝗻𝘁 from the 𝗠𝗮𝗿𝘆𝗹𝗮𝗻𝗱 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗙𝘂𝗻𝗱 (𝗠𝗦𝗖𝗥𝗙), supporting life-saving stem cell research. Thanks to MSCRF & TEDCO — exciting updates are ahead!

Find out more: www.tedcomd.com/news-events/...
Maryland Stem Cell Research Fund Awards $4.7 million to Support Innovations in Stem Cell Research | TEDCO
The grants will drive research and development programs in regenerative medicine across Maryland
www.tedcomd.com
October 8, 2025 at 7:08 AM
🔥Could iMSCs be the future of burn care? A new study shows that iMSCs derived from iPSCs significantly accelerate healing of full-thickness burns in pigs — pointing to their potential in regenerative medicine.

Study: hubs.li/Q03LTwgq0

Our iMSC products: hubs.li/Q03LTwc_0
Human iPSCs-derived mesenchymal stem cells promote skin regeneration and burn wound healing - npj Regenerative Medicine
npj Regenerative Medicine - Human iPSCs-derived mesenchymal stem cells promote skin regeneration and burn wound healing
hubs.li
October 3, 2025 at 10:06 AM
REPROCELL now offers our gene-engineered 𝗵𝘆𝗽𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗶𝗣𝗦𝗖𝘀 (𝗕𝟮𝗠 𝗼𝗿 𝗱𝘂𝗮𝗹 𝗕𝟮𝗠 + 𝗖𝗜𝗜𝗧𝗔 𝗸𝗻𝗼𝗰𝗸𝗼𝘂𝘁𝘀) in combination with the unmodified parental StemRNA™ iPSC line—a bundle ideal for robust experimental design.

👉 𝗢𝘂𝗿 𝗶𝗣𝗦𝗖𝘀 𝗮𝗿𝗲 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲.

🌐 hubs.li/Q03GqzMM0
StemEdit Hypoimmune iPSCs
Discover REPROCELL's StemEdit™ hypoimmune iPSC lines, enabling advanced immune research and clinical applications with high-quality genome editing technology and regulatory-compliant cell lines.
hubs.li
September 30, 2025 at 12:45 PM